Cambridge biotech co. taking bets on HCV drug

The In-Vivo blog reports that Vertex is selling off anticipated payments the Cambridge biotech hopes to earn from a drug development deal.

Vertex announced this morning that it intended to sell (to an unnamed buyer) its future milestone payments associated with the filing, approval and launch of telaprevir in Europe.

Telaprevir is a promising drug for Hepatitis C. This is a case of a big fish betting on a smaller fish. Then, the smaller fish tries to sell off potential future pay-outs on that bet.

fc merck scout 1For more on this phenom, see my 2007 story in Fast Company magazine.



Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s